Investigational drug · Phase 2
HS-10542
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "HS-10542"
First trial start
2026
Feb 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-10542", any sponsor or status.
Conditions studied
As listed on its trial records.
- IgAN
- Immunoglobulin A Nephropathy (IgAN)
- Glomerular Disease
- Paroxysmal Nocturnal Hemoglobinuria
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-10542" as an intervention, largest first.
- HS-10542 Study in Healthy ParticipantsPivotal-lookingRecruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07040046 · 100 participants (planned) · Start May 16, 2025 · Primary completion Dec 4, 2025
Drug: HS-10542; HS-10542 Placebo and 2 more · For: Healthy
Sites: Qingdao, China
- Efficacy and Safety Study of HS-10542 for IgA NephropathyNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07474636 · 90 participants (planned) · Start Mar 17, 2026 · Primary completion Dec 10, 2027
Drug: HS-10542 High Dose; HS-10542 Low Dose and 1 more · For: IgAN; Immunoglobulin A Nephropathy (IgAN); Glomerular Disease
Sites: Beijing, China
- Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal HemoglobinuriaRecruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07470762 · 50 participants (planned) · Start Feb 14, 2026 · Primary completion May 30, 2027
Drug: HS-10542; HS-10542 and 1 more · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for IgAN
- siRNAADX-038, ADX-324Phase 37 trials
ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1
- FXS6837Phase 34 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Paroxysmal Nocturnal Hemoglobinuria, Primary IgAN, IgAN
- STL303Phase 22 trials
Sitala Bio LTD · IgAN, Geographic Atrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.